North America Ophthalmology Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2023 –2030 |
 Market Size (Base Year) |
USD 20,704.35 Million |
 Market Size (Forecast Year) |
USD 34,946.97 Million |
 CAGR |
% |
| Major Markets Players |
>北美眼科市场，按产品（设备、药品和其他）、疾病（青光眼、白内障、老年性黄斑变性、炎症性疾病、屈光不正等）、处方模式（通用和品牌）、药品类型（处方药和非处方药）、给药途径（口服、外用、注射剂、局部眼部和其他）、最终用户（医院、诊所、家庭医疗保健等）、分销渠道（直接招标、零售销售等） - 行业趋势和预测到 2030 年。
北美眼科市场分析及规模
推动眼科市场增长的主要因素之一是眼科疾病和眼痛的患病率不断上升。多家制药企业正在进行临床试验研究，以寻求更好的治疗选择，接触某些毒素或环境变化，这增加了眼科产品的发生率并导致市场扩张。不卫生和久坐的生活方式的增加以及创伤性损伤的增加也影响了市场。然而，眼科手术和治疗的高成本和风险、人口缺乏健康保险（尤其是在发展中国家）以及制造和配制眼科药物的时间过长，这些都成为预测期内北美眼科市场发展的制约因素。
北美眼科市场预计将在 2023 年至 2030 年的预测期内实现市场增长。Data Bridge Market Research 分析称，在 2023 年至 2030 年的预测期内，该市场将以 6.8% 的复合年增长率增长，预计到 2030 年将从 2022 年的 207.0435 亿美元达到 349.4697 亿美元。
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021 (可定制为 2015-2020) |
|
定量单位 |
收入（百万美元） |
|
涵盖的领域 |
按产品类型（设备、药品和其他）、疾病（青光眼、白内障、老年性黄斑变性、炎症性疾病、屈光不正等）、处方模式（通用和品牌）、药品类型（处方药和非处方药 (OTC)）、给药途径（口服、外用、注射剂、局部眼部和其他）、最终用户（医院、诊所、家庭医疗保健等）、分销渠道（直接招标、零售销售等） |
|
覆盖国家 |
美国、加拿大和墨西哥。 |
|
涵盖的市场参与者 |
Alcon、Regeneron Pharmaceuticals Inc.、Johnson & Johnson, Inc.、Reichert, Inc.、Novartis AG、Bausch & Lomb Incorporated、HOYA Corporation.、The Cooper Companies Inc.、Santen Pharmaceutical Co., Ltd.、F. Hoffmann-La Roche Ltd、Carl Zeiss Meditec AG、AbbVie Inc.、EssilorLuxottica、NIDEK CO., LTD.、TOPCON CORPORATION、Glaukos Corporation.、STAAR SURGICAL、Metall Zug AG、Sun Pharmaceutical Industries Ltd.、Lumenis Be Ltd.、Pfizer Inc. 和 Ziemer Ophthalmic Systems AG 等。 |
市场定义
眼科学是医学的一个分支，涉及眼睛视觉通路的解剖学、生理学、治疗和手术，包括周围区域和大脑的视觉方面。眼科设备是专为手术、诊断和视力矫正而设计的医疗设备。由于青光眼、白内障和其他视力相关问题等多种眼科疾病的患病率很高，这些设备的重要性和采用率也越来越高。眼科药物是专门为治疗各种眼部疾病而设计和使用的药物，包括色盲、糖尿病性黄斑水肿、巨细胞病毒(CMV) 和老年性黄斑变性 (AMD)。
眼科市场动态
本节旨在了解市场驱动因素、优势、机遇、限制和挑战。下面将详细讨论所有这些内容：
驱动程序
- 眼科疾病和眼痛患病率不断上升
眼部疾病是导致眼部和眼眶疼痛的重要原因。眼部疼痛发生在眼部表面，并伴有抓挠、灼热或瘙痒等症状。这可能是由于多种原因造成的，包括异物刺激、感染或创伤。睫毛或污垢、烟雾、灰尘或一些刺激性眼部化妆品是导致眼部疼痛、发红和流泪的常见原因。
随着全球化学工业和污染的不断增长，眼痛的患病率不断上升。化学灼伤和闪光灼伤会因眼表刺激而导致严重而剧烈的眼痛。眼睑炎和睑缘炎会导致严重的眼痛，因为它们会使眼部和油腺更加敏感。肯定因素表明这是北美眼科市场的主要驱动力。
- 创伤性损伤增加
创伤性头部损伤是导致视神经疾病等疾病的原因之一。创伤性损伤是一种突然发生的具有一定严重程度的身体损伤。创伤可以由多种外伤引起。最常见的创伤性损伤原因包括道路事故、运动损伤和暴力等，这些损伤也可能导致一些严重的眼部疾病。这种创伤性损伤在世界范围内的患病率很高。
因此，此类创伤会导致视神经疾病，这些疾病近年来影响着人口，并且随着人口的增加而增加。因此，创伤的增加预计将推动市场增长。
机会
-
医疗支出和可支配收入增加
医疗保健支出及其随时间的增长率受到多种经济和社会因素的影响，包括融资安排和卫生系统的组织结构。
随着各国人民的可支配收入不断增加，全球医疗支出也随之增加。此外，为满足人口需求，政府机构和医疗机构正采取积极措施，加快医疗支出。
医疗支出的增长也有利于进一步的经济增长和医疗保健行业的增长。它的主要成果是，它显著影响了市场上更好、更先进的医疗产品的开发。因此，医疗支出的激增可能成为市场增长的绝佳机会。
-
提高预防眼疾负担的意识
世界卫生组织 (WHO) 及其成员国、联合国机构、非政府组织 (NGO) 和私营部门等各组织在预防视力障碍方面取得了重大进展，以对抗可见疾病。因此，10 月的第二个星期四是世界视觉日 (WSD)，这是一个每年一度的宣传日，旨在引起北美对失明和视力障碍的关注。
因此，预计减轻眼疾负担的计划和举措将在预测期内为北美眼科市场的增长创造机会。
限制/挑战
- 眼科手术和治疗的高成本和风险
各种疾病的治疗成本在市场中起着重要作用。视神经疾病的治疗非常复杂，因为此类疾病的患病率正在增加；因此对此类产品的需求最终会增加，从而提高治疗成本，这可能会阻碍未来几年的市场增长。
治疗视神经炎的方法有很多种。其中一些方法包括患者可以服用各种药物，如皮质类固醇（如甲基强的松龙、泼尼松龙）、免疫球蛋白、维生素 B12 注射剂和各种其他手术。这些方法都存在一些风险。
因此，对于全国部分人口来说，由于费用高昂，他们很难接受此类治疗。因此，与眼科疾病治疗相关的高成本预计将抑制市场增长。
- 缺乏熟练的专业人员
新兴国家和工业化国家的眼科医生数量都很少。但是，发展中国家的预测数字略高一些。眼科医生的数量是累积的，但不如需要加强眼科护理的 60 岁或以上老年患者人口的增长速度快。在大多数国家，问题在于人口变化与专业发展不匹配。需要培训眼科护理团队以满足目前全球眼科医生的数量。全球对眼科医生需求的增加也反映了糖尿病病例的增加。糖尿病患者应该每年都接受眼科检查。对眼科医生的需求不断增长与老年人口的增长成正比，因为眼科护理是医疗保健不可或缺的一部分。可以通过结合多种因素来弥补获得护理的差距，包括更有效的实践结构、流程和适当使用技术。
后新冠疫情对眼科市场的影响
COVID-19 疫情对眼科和外科手术行业产生了巨大影响。眼科和视力产品行业的贸易团体声称，北美手术、诊断和视力护理产品的供应链已严重受损，影响了眼科市场的终端用户消费。由于物流和运输问题，2020 年第一季度视力护理产品的销售大幅延迟。在需求方面，由于封锁结束后人们必须接受手术，市场正在增长。需要考虑这种情况，并需要进行紧急手术。此外，在供应方面，市场的增长呈负增长。这是由于许多生产诊断、手术和视力护理仪器的国家处于封锁状态。
最新动态
- 2022 年 10 月，Regeneron Pharmaceuticals, Inc. 宣布美国食品药品监督管理局 (FDA) 已接受 EYLEA (阿柏西普) 注射剂的补充生物制品许可申请 (sBLA) 进行优先审查，该注射剂用于治疗早产儿视网膜病变 (ROP)。这一进展有助于该组织在眼科市场等市场树立品牌形象
- 2022 年 5 月，Reichert, Inc. 推出了重新设计的折射仪和分析仪器网站，用户体验得到了极大改善
北美眼科市场范围
北美眼科市场细分为产品、疾病、处方模式、药物类型、给药途径、最终用户和分销渠道。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场，并为用户提供有价值的市场概览和市场洞察，以便做出战略决策，确定核心市场应用。
产品
- 设备
- 药物
- 其他的
根据产品，眼科市场分为设备、药品和其他。
疾病
- 青光眼
- 白内障
- 年龄相关性黄斑变性
- 炎症性疾病
- 屈光不正
- 其他的
根据疾病，眼科市场分为青光眼、白内障、老年性黄斑变性、炎症性疾病、屈光不正等。
处方模式
- 通用的
- 品牌
根据处方模式，眼科市场分为仿制药和品牌药。
药物类型
- 处方
- 场外交易 (OTC)
根据药品类型，眼科市场分为处方药和非处方药（OTC）。
给药途径
- 口服
- 主题
- 注射剂
- 局部眼科
- 其他的
根据给药途径，眼科市场分为口服、外用、注射、局部眼部和其他。
最终用户
- 医院
- 诊所
- 家庭医疗保健
- 其他的
根据最终用户，眼科市场分为医院、诊所、家庭医疗保健和其他。
分销渠道
- 直接招标
- 零售销售
- 其他的
根据分销渠道，眼科市场分为直接招标、零售和其他。
眼科市场区域分析/见解
北美垫片市场根据产品、疾病、处方模式、药物类型、给药途径、最终用户和分销渠道进行细分。
北美垫片市场的国家包括美国、加拿大和墨西哥。
美国占据主导地位，因为对眼科产品的需求增加，并且该行业研发活动的增加预计也将在预测期内推动市场发展。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和市场监管变化。数据点下游和上游价值链分析、技术趋势、波特五力分析和案例研究是用于预测各个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了北美品牌的存在和可用性以及由于来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税的影响和贸易路线。
竞争格局和北美眼科市场份额分析
眼科市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、北美业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与专注于北美眼科市场的公司有关。
该市场的一些主要参与者包括 Alcon、Regeneron Pharmaceuticals Inc.、Johnson & Johnson, Inc.、Reichert, Inc.、Novartis AG、Bausch & Lomb Incorporated、HOYA Corporation.、The Cooper Companies Inc.、Santen Pharmaceutical Co., Ltd.、F. Hoffmann-La Roche Ltd、Carl Zeiss Meditec AG、AbbVie Inc.、EssilorLuxottica、NIDEK CO., LTD.、TOPCON CORPORATION、Glaukos Corporation.、STAAR SURGICAL、Metall Zug AG、Sun Pharmaceutical Industries Ltd.、Lumenis Be Ltd.、Pfizer Inc. 和 Ziemer Ophthalmic Systems AG 等。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA OPHTHALMOLOGY MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 NORTH AMERICA OPHTHALMOLOGY MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT SEGMENT LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 EPIDEMIOLOGY
6 STRATEGIC INITIATIVES
7 NORTH AMERICA OPHTHALMOLOGY MARKET, REGULATION
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 RISING PREVALENCE OF OPHTHALMIC DISORDERS & OCULAR PAINS
8.1.2 INCREASING UNHYGIENIC & SEDENTARY LIFESTYLE
8.1.3 RISE IN TRAUMATIC INJURIES
8.1.4 RISE IN THE GERIATRIC POPULATION
8.2 RESTRAINTS
8.2.1 HIGH COST & RISKS ASSOCIATED WITH EYE SURGERY & TREATMENT
8.2.2 LACK OF HEALTH INSURANCE AMONGST THE POPULATION, ESPECIALLY WITHIN THE DEVELOPING COUNTRIES
8.2.3 SIDE EFFECTS ASSOCIATED WITH TREATMENT DRUGS
8.3 OPPORTUNITIES
8.3.1 RISE IN HEALTHCARE EXPENDITURE AND DISPOSABLE INCOME
8.3.2 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS
8.3.3 RISING AWARENESS TO PREVENT THE BURDEN OF EYE DISEASES
8.4 CHALLENGE
8.4.1 LACK OF SKILLED PROFESSIONALS
8.4.2 STRINGENT RULES & REGULATIONS FOR PRODUCT APPROVAL
9 NORTH AMERICA OPHTHALMOLOGY MARKET, BY PRODUCTS
9.1 OVERVIEW
9.2 DEVICE
9.2.1 SURGICAL DEVICE
9.2.1.1 CATARACT SURGICAL DEVICES
9.2.1.2 OPHTHALMIC VISCOELASTIC DEVICES
9.2.1.2.1 PHACOEMULSIFICATION DEVICES
9.2.1.2.2 CATARACT SURGICAL LASERS
9.2.1.2.3 IOL INJECTORS
9.2.1.3 VITREORETINAL SURGICAL DEVICES
9.2.1.3.1 VITREORETINAL PACKS
9.2.1.3.2 VITRECTOMY MACHINES
9.2.1.3.3 VITRECTOMY PROBES
9.2.1.3.4 PHOTOCOAGULATION LASERS
9.2.1.3.5 ILLUMINATION DEVICES
9.2.1.4 REFRACTIVE SURGICAL DEVICES
9.2.1.4.1 FEMTOSECOND LASERS
9.2.1.4.2 EXCIMER LASERS
9.2.1.4.3 OTHER REFRACTIVE SURGICAL LASERS
9.2.1.5 GLAUCOMA SURGICAL DEVICES
9.2.1.5.1 GLAUCOMA DRAINAGE DEVICES
9.2.1.5.2 GLAUCOMA LASER SYSTEMS
9.2.1.5.3 MICRO INVASIVE GLAUCOMA SURGERY DEVICES
9.2.2 DIAGNOSTIC DEVICE
9.2.2.1 AUTOREFRACTORS & KERATOMETERS
9.2.2.2 TONOMETER
9.2.2.3 PHOROPTERS
9.2.2.4 RETINOSCOPES
9.2.2.5 OPHTHALMOSCOPES
9.2.2.6 PERIMETERS/VISUAL FIELD ANALYZERS
9.2.2.7 OPHTHALMIC ULTRASOUND IMAGING SYSTEMS
9.2.2.7.1 A- SCAN IMAGING SYSTEM
9.2.2.7.2 B-SCAN IMAGING SYSTEM
9.2.2.7.3 PACHYMETERS
9.2.2.7.4 ULTRASOUND BIOMICROSCOPES
9.2.2.8 LENSMETERS
9.2.2.9 CORNEAL TOPOGRAPHY SYSTEMS
9.2.2.10 OPTICAL COHERENCE TOMOGRAPHY SCANNERS
9.2.2.11 FUNDUS CAMERAS
9.2.2.12 OPTICAL BIOMETRY SYSTEMS
9.2.2.13 SPECULAR MICROSCOPES
9.2.2.14 WAVEFRONT ABERROMETERS
9.2.2.15 CHART PROJECTORS
9.2.2.16 SLIT LAMPS
9.2.3 OPHTHALMIC SURGICAL ACCESSORIES
9.2.3.1 SURGICAL INSTRUMENTS & KITS
9.2.3.2 OPHTHALMIC FORCEPS
9.2.3.3 OPHTHALMIC SPATULA
9.2.3.4 OPHTHALMIC TIPS AND HANDLES
9.2.3.5 OPHTHALMIC CANNULAS
9.2.3.6 OPHTHALMIC SCISSORS
9.2.3.7 OTHERS SURGICAL ACCESSORIES
9.2.4 OPHTHALMIC MICROSCOPES
9.3 DRUGS
9.3.1 ANTI-INFLAMMATION DRUGS
9.3.1.1 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
9.3.1.2 STEROIDAL ANTI-INFLAMMATORY DRUGS
9.3.2 ALLERGIC CONJUNCTIVITIS
9.3.3 DRY EYE DRUGS
9.3.4 RETINAL DISORDER DRUGS
9.3.5 ANTI-GLAUCOMA DRUGS
9.3.5.1 MIOTICS
9.3.5.1.1 PILOCARPINE
9.3.5.1.2 ESERINE
9.3.5.2 BETA ADRENERGIC ANTAGONISTS
9.3.5.2.1 TIMOLAL MALEATE
9.3.5.2.2 BETAXOLOL
9.3.5.3 PROSTAGLANDIN ANALOGS
9.3.5.3.1 LATANOPROST
9.3.5.3.2 BIMATOPROST
9.3.5.3.3 TRAVOPROST
9.3.5.3.4 TAFLUPROST
9.3.5.3.5 LATANOPROSTENE
9.3.5.4 ALPHA ADRENERGIC AGONISTS
9.3.5.4.1 EPINEPHRINE
9.3.5.4.2 DEPIVEPRINE
9.3.5.5 ANTI-VEGF DRUGS
9.3.5.5.1 RANIBIZUMAB
9.3.5.5.2 BEVACIZUMAB
9.3.6 OTHERS
9.4 OTHERS
9.4.1 VISION CARE PRODUCTS
9.4.1.1 SPECTACLES
9.4.1.2 CONTACT LENSES
9.4.1.2.1 SOFT CONTACT LENSES
9.4.1.2.2 HYBRID CONTACT LENSES
9.4.1.2.3 RIGID GAS PERMEABLE LENSES
9.4.2 OTHERS
10 NORTH AMERICA OPHTHALMOLOGY MARKET, BY DISEASES
10.1 OVERVIEW
10.2 INFLAMMATORY DISEASES
10.3 CATARACT
10.4 REFRACTIVE DISORDERS
10.5 GLAUCOMA
10.6 AGE-RELATED MACULAR DEGENERATION
10.7 OTHERS
11 NORTH AMERICA OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE
11.1 OVERVIEW
11.2 BRANDED
11.3 GENERIC
12 NORTH AMERICA OPHTHALMOLOGY MARKET, BY DRUG TYPE
12.1 OVERVIEW
12.2 OVER THE COUNTER
12.3 PRESCRIPTION
13 NORTH AMERICA OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION
13.1 OVERVIEW
13.2 TOPICAL
13.2.1 EYE DROPS
13.2.2 EYE SOLUTION
13.2.3 CREAM & OINTMENTS
13.2.4 GEL
13.2.5 OTHERS
13.3 ORAL
13.3.1 TABLET
13.3.2 CAPSULES
13.3.3 OTHERS
13.4 LOCAL OCULAR
13.4.1 SUBCONJUNCTIVAL
13.4.2 INTRAVITREAL
13.4.3 RETROBULBAR
13.4.4 INTRACAMERAL
13.5 INJECTABLE
13.5.1 INTRAMUSCULAR
13.5.2 INTRAVENOUS
13.5.3 OTHERS
13.6 OTHERS
14 NORTH AMERICA OPHTHALMOLOGY MARKET, BY END USER
14.1 OVERVIEW
14.2 CLINICS
14.3 HOSPITALS
14.4 HOMECARE SETTINGS
14.5 OTHERS
15 NORTH AMERICA OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 RETAIL SALES
15.2.1 RETAIL SHOPS
15.2.2 HOSPITAL PHARMACY
15.2.3 ONLINE PHARMACY
15.3 DIRECT TENDER
15.4 OTHERS
16 NORTH AMERICA OPHTHALMOLOGY MARKET, BY GEOGRAPHY
16.1 NORTH AMERICA
16.1.1 U.S.
16.1.2 CANADA
16.1.3 MEXICO
17 NORTH AMERICA OPHTHALMOLOGY MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 ALCON
19.1.1 COMPANY SNAPSHOT
19.1.2 RECENT FINANCIALS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 REGENERON PHARMACEUTICALS INC.
19.2.1 COMPANY SNAPSHOT
19.2.2 RECENT FINANCIALS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENT
19.3 JOHNSON & JOHNSON SERVICES, INC.
19.3.1 COMPANY SNAPSHOT
19.3.2 RECENT FINANCIALS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENT
19.4 REICHERT, INC.
19.4.1 COMPANY SNAPSHOT
19.4.2 COMPANY SHARE ANALYSIS
19.4.3 PRODUCT PORTFOLIO
19.4.4 RECENT DEVELOPMENT
19.5 NOVARTIS AG
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENTS
19.6 ABBVIE INC.
19.6.1 COMPANY SNAPSHOT
19.6.2 RECENT FINANCIALS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENT
19.7 BAUSCH & LOMB INCORPORATED
19.7.1 COMPANY SNAPSHOT
19.7.2 REVENUE ANALYSIS
19.7.3 PRODUCT PORTFOLIO
19.7.4 RECENT DEVELOPMENTS
19.8 CARL ZEISS MEDITEC AG
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENTS
19.9 ESSILORLUXOTTICA
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT DEVELOPMEN
19.1 F. HOFFMANN- LA ROCHE LTD
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORTFOLIO
19.10.4 RECENT DEVELOPMENT
19.11 GLAUKOS
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENTS
19.12 HEIDELBERG ENGINEERING GMBH
19.12.1 COMPANY SNAPSHOT
19.12.2 PRODUCT PORTFOLIO
19.12.3 RECENT DEVELOPMENT
19.13 HOYA CORPORATION
19.13.1 COMPANY SNAPSHOT
19.13.2 REVENUE ANALYSIS
19.13.3 PRODUCT PORTFOLIO
19.13.4 RECENT DEVELOPMENTS
19.14 LUMENIS BE LTD.
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENT
19.15 METALL ZUG AG
19.15.1 COMPANY SNAPSHOT
19.15.2 REVENUE ANALYSIS
19.15.3 PRODUCT PORTFOLIO
19.15.4 RECENT DEVELOPMENT
19.16 NEOVISION
19.16.1 COMPANY SNAPSHOT
19.16.2 PRODUCT PORTFOLIO
19.16.3 RECENT DEVELOPMENT
19.17 NIDEK CO., LTD.
19.17.1 COMPANY SNAPSHOT
19.17.2 PRODUCT PORTFOLIO
19.17.3 RECENT DEVELOPMENT
19.18 PFIZER INC.
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENT
19.19 SANTEN PHARMACEUTICAL CO., LTD.
19.19.1 COMPANY SNAPSHOT
19.19.2 RECENT FINANCIALS
19.19.3 PRODUCT PORTFOLIO
19.19.4 RECENT DEVELOPMENTS
19.2 SUN PHARMACEUTICAL INDUSTRIES LTD.
19.20.1 COMPANY SNAPSHOT
19.20.2 RECENT FINANCIALS
19.20.3 PRODUCT PORTFOLIO
19.20.4 RECENT DEVELOPMENTS
19.21 STAAR SURGICAL
19.21.1 COMPANY SNAPSHOT
19.21.2 REVENUE ANALYSIS
19.21.3 PRODUCT PORTFOLIO
19.21.4 RECENT DEVELOPMENTS
19.22 THE COOPER COMPANIES INC.
19.22.1 COMPANY SNAPSHOT
19.22.2 REVENUE ANALYSIS
19.22.3 PRODUCT PORTFOLIO
19.22.4 RECENT DEVELOPMENTS
19.23 TOPCON CORPORATION
19.23.1 COMPANY SNAPSHOT
19.23.2 REVENUE ANALYSIS
19.23.3 PRODUCT PORTFOLIO
19.23.4 RECENT DEVELOPMENTS
19.24 VISIONIX
19.24.1 COMPANY SNAPSHOT
19.24.2 PRODUCT PORTFOLIO
19.24.3 RECENT DEVELOPMENT
19.25 ZIEMER OPHTHALMIC SYSTEMS AG
19.25.1 COMPANY SNAPSHOT
19.25.2 PRODUCT PORTFOLIO
19.25.3 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
表格列表
TABLE 1 NORTH AMERICA OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2 NORTH AMERICA DEVICE IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 NORTH AMERICA DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 4 NORTH AMERICA SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 5 NORTH AMERICA OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 6 NORTH AMERICA VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 7 NORTH AMERICA REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 8 NORTH AMERICA GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 9 NORTH AMERICA DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 10 NORTH AMERICA OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 11 NORTH AMERICA OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 12 NORTH AMERICA DRUGS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 NORTH AMERICA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 14 NORTH AMERICA ANTI INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 15 NORTH AMERICA ANTI GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 16 NORTH AMERICA MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 17 NORTH AMERICA BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 18 NORTH AMERICA PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 19 NORTH AMERICA ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 20 NORTH AMERICA ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 21 NORTH AMERICA OTHERS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 NORTH AMERICA OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 23 NORTH AMERICA VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 24 NORTH AMERICA CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION))
TABLE 25 NORTH AMERICA OPHTHALMOLOGY MARKET, BY DISEASES 2021-2030 (USD MILLION)
TABLE 26 NORTH AMERICA INFLAMMATORY DISEASES IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 27 NORTH AMERICA CATARACT IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 NORTH AMERICA REFRACTIVE DISORDERS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 NORTH AMERICA GLAUCOMA IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 NORTH AMERICA OTHERS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 NORTH AMERICA OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 33 NORTH AMERICA BRANDED IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 34 NORTH AMERICA GENERIC IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 NORTH AMERICA OPHTHALMOLOGY MARKET, BY DRUG TYPE 2021-2030 (USD MILLION)
TABLE 36 NORTH AMERICA OVER THE COUNTER IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 37 NORTH AMERICA PRESCRIPTION IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 38 NORTH AMERICA OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 39 NORTH AMERICA TOPICAL IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 NORTH AMERICA TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 41 NORTH AMERICA ORAL IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 NORTH AMERICA ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 43 NORTH AMERICA LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 44 NORTH AMERICA LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 45 NORTH AMERICA INJECTABLES IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 NORTH AMERICA INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 47 NORTH AMERICA OTHERS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 48 NORTH AMERICA OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 49 NORTH AMERICA CLINICS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 50 NORTH AMERICA HOSPITALS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 51 NORTH AMERICA HOME HEALTHCARE IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 52 NORTH AMERICA OTHERS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 53 NORTH AMERICA OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 54 NORTH AMERICA RETAIL SALES IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 55 NORTH AMERICA RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL 2021-2030 (USD MILLION)
TABLE 56 NORTH AMERICA DIRECT TENDER IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 57 NORTH AMERICA OTHERS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 58 NORTH AMERICA OPHTHALMOLOGY MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 59 NORTH AMERICA OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 60 NORTH AMERICA DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 61 NORTH AMERICA SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 62 NORTH AMERICA OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 63 NORTH AMERICA VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 64 NORTH AMERICA VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 65 NORTH AMERICA GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 66 NORTH AMERICA DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 67 NORTH AMERICA OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 68 NORTH AMERICA OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 69 NORTH AMERICA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 70 NORTH AMERICA ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 71 NORTH AMERICA ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 72 NORTH AMERICA MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 73 NORTH AMERICA BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 74 NORTH AMERICA PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 75 NORTH AMERICA ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 76 NORTH AMERICA ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 77 NORTH AMERICA OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 78 NORTH AMERICA VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 79 NORTH AMERICA CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 80 NORTH AMERICA OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 81 NORTH AMERICA OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 82 NORTH AMERICA OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 83 NORTH AMERICA OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 84 NORTH AMERICA TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 85 NORTH AMERICA ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 86 NORTH AMERICA LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 87 NORTH AMERICA INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 88 NORTH AMERICA OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 89 NORTH AMERICA OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 90 NORTH AMERICA RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 91 U.S. OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 92 U.S. DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 93 U.S. SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 94 U.S. OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 95 U.S. VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 96 U.S. REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 97 U.S. GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 98 U.S. DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 99 U.S. OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 100 U.S. OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 101 U.S. DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 102 U.S. ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 103 U.S. ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 104 U.S. MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 105 U.S. BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 106 U.S. PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 107 U.S. ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 108 U.S. ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 109 U.S. OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 110 U.S. VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 111 U.S. CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 112 U.S. OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 113 U.S. OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 114 U.S. OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 115 U.S. OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 116 U.S. TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 117 U.S. ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 118 U.S. LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 119 U.S. INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 120 U.S. OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 121 U.S. OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 122 U.S. RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 123 CANADA OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 124 CANADA DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 125 CANADA SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 126 CANADA OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 127 CANADA VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 128 CANADA REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 129 CANADA GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 130 CANADA DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 131 CANADA OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 132 CANADA OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 133 CANADA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 134 CANADA ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 135 CANADA ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 136 CANADA MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 137 CANADA BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 138 CANADA PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 139 CANADA ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 140 CANADA ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 141 CANADA OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 142 CANADA VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 143 CANADA CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 144 CANADA OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 145 CANADA OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 146 CANADA OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 147 CANADA OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 148 CANADA TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 149 CANADA ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 150 CANADA LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 151 CANADA INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 152 CANADA OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 153 CANADA OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 154 CANADA RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 155 MEXICO OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 156 MEXICO DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 157 MEXICO SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 158 MEXICO OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 159 MEXICO VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 160 MEXICO REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 161 MEXICO GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 162 MEXICO DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 163 MEXICO OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 164 MEXICO OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 165 MEXICO DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 166 MEXICO ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 167 MEXICO ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 168 MEXICO MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 169 MEXICO BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 170 MEXICO PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 171 MEXICO ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 172 MEXICO ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 173 MEXICO OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 174 MEXICO VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 175 MEXICO CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 176 MEXICO OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 177 MEXICO OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 178 MEXICO OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 179 MEXICO OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 180 MEXICO TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 181 MEXICO ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 182 MEXICO LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 183 MEXICO INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 184 MEXICO OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 185 MEXICO OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 186 MEXICO RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
图片列表
FIGURE 1 NORTH AMERICA OPHTHALMOLOGY MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA OPHTHALMOLOGY MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA OPHTHALMOLOGY MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA OPHTHALMOLOGY MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA OPHTHALMOLOGY MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA OPHTHALMOLOGY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA OPHTHALMOLOGY MARKET: DBMR POSITION GRID
FIGURE 8 NORTH AMERICA OPHTHALMOLOGY MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 NORTH AMERICA OPHTHALMOLOGY MARKET: END USER COVERAGE GRID
FIGURE 10 NORTH AMERICA OPHTHALMOLOGY MARKET: SEGMENTATION
FIGURE 11 RISING PREVALENCE OF OPHTHALMIC DISORDERS& INCREASING GERIATRIC POPULATION ARE EXPECTED TO DRIVE THE NORTH AMERICA OPHTHALMOLOGY MARKET FROM 2022 TO 2029
FIGURE 12 THE DEVICE SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE NORTH AMERICA OPHTHALMOLOGY MARKET FROM 2022 TO 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA OPHTHALMOLOGY MARKET
FIGURE 14 NORTH AMERICA OPHTHALMOLOGY MARKET: BY PRODUCTS, 2022
FIGURE 15 NORTH AMERICA OPHTHALMOLOGY MARKET: BY PRODUCTS, 2023-2030 (USD MILLION)
FIGURE 16 NORTH AMERICA OPHTHALMOLOGY MARKET: BY PRODUCTS, CAGR (2023-2030)
FIGURE 17 NORTH AMERICA OPHTHALMOLOGY MARKET: BY PRODUCTS, LIFELINE CURVE
FIGURE 18 NORTH AMERICA OPHTHALMOLOGY MARKET: BY DISEASES, 2022
FIGURE 19 NORTH AMERICA OPHTHALMOLOGY MARKET: BY DISEASES, 2023-2030 (USD MILLION)
FIGURE 20 NORTH AMERICA OPHTHALMOLOGY MARKET: BY DISEASES, CAGR (2023-2030)
FIGURE 21 NORTH AMERICA OPHTHALMOLOGY MARKET: BY DISEASES, LIFELINE CURVE
FIGURE 22 NORTH AMERICA OPHTHALMOLOGY MARKET: BY PRESCRIPTION MODE ,2022
FIGURE 23 NORTH AMERICA OPHTHALMOLOGY MARKET: BY PRESCRIPTION MODE, 2023-2030 (USD MILLION)
FIGURE 24 NORTH AMERICA OPHTHALMOLOGY MARKET: BY PRESCRIPTION MODE, CAGR (2023-2030)
FIGURE 25 NORTH AMERICA OPHTHALMOLOGY MARKET: BY PRESCRIPTION MODE, LIFELINE CURVE
FIGURE 26 NORTH AMERICA OPHTHALMOLOGY MARKET: BY DRUG TYPE ,2022
FIGURE 27 NORTH AMERICA OPHTHALMOLOGY MARKET: BY DRUG TYPE, 2023-2030 (USD MILLION)
FIGURE 28 NORTH AMERICA OPHTHALMOLOGY MARKET: BY DRUG TYPE, CAGR (2023-2030)
FIGURE 29 NORTH AMERICA OPHTHALMOLOGY MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 30 NORTH AMERICA OPHTHALMOLOGY MARKET: BY ROUTE OF ADMINISTRATION, 2022
FIGURE 31 NORTH AMERICA OPHTHALMOLOGY MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
FIGURE 32 NORTH AMERICA OPHTHALMOLOGY MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)
FIGURE 33 NORTH AMERICA OPHTHALMOLOGY MARKET : BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 34 NORTH AMERICA OPHTHALMOLOGY MARKET: BY END USER, 2022
FIGURE 35 NORTH AMERICA OPHTHALMOLOGY MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 36 NORTH AMERICA OPHTHALMOLOGY MARKET: BY END USER, CAGR (2023-2030)
FIGURE 37 NORTH AMERICA OPHTHALMOLOGY MARKET: BY END USER, LIFELINE CURVE
FIGURE 38 NORTH AMERICA OPHTHALMOLOGY MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 39 NORTH AMERICA OPHTHALMOLOGY MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 40 NORTH AMERICA OPHTHALMOLOGY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 41 NORTH AMERICA OPHTHALMOLOGY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 42 NORTH AMERICA OPHTHALMOLOGY MARKET: SNAPSHOT (2022)
FIGURE 43 NORTH AMERICA OPHTHALMOLOGY MARKET: BY COUNTRY (2022)
FIGURE 44 NORTH AMERICA OPHTHALMOLOGY MARKET: BY COUNTRY (2023 & 2030)
FIGURE 45 NORTH AMERICA OPHTHALMOLOGY MARKET: BY COUNTRY (2022 & 2030)
FIGURE 46 NORTH AMERICA OPHTHALMOLOGY MARKET: PRODUCTS (2023-2030)
FIGURE 47 NORTH AMERICA OPHTHALMOLOGY MARKET: COMPANY SHARE 2022 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
